Lunaphore launches the 2022 COMET™ Grant Program, open to all discovery and translational labs in order to further spatial biology research

Lunaphore launches the 2022 COMET™ Grant Program, open to all discovery and translational labs in order to further spatial biology research

LAUSANNE, Switzerland – October 24, 2022 – 4:00 pm (CEST)Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, today announced the 2022 COMET™ Grant Program, designed to further spatial biology research by awarding a four-month COMET™ placement to a winning applicant. The grant application is open to all discovery and translational labs located in Europe or the US. Following the success of the 2021 Immuno-Oncology Grant Program, Lunaphore aims that the COMET™ Grant Program will incentivize data generation more broadly as well as lower the barriers to spatial technology adoption. Aligned with the overarching goal of bringing awareness to the latest research and innovation leading the spatial biology revolution, the grant program will support the company’s mission of making spatial biology mainstream.

Research projects can be in any field of scientific research, including, but not limited to, immuno-oncology, oncology, neuroscience, and infectious diseases. The technology placement will be awarded to the best project, based on its scientific impact and technology fit, and will require the submission of a project hypothesis and details around how COMET™ will be used in the scope of the project.

Applicants must be employed at a Research Institution (private or academic), Healthcare Organization (HCO), a Pharma / Biotech company, or a Contract Research Organization (CRO). The submission period will be open from October 24 – December 9, 2022, with the winner announced on December 16, 2022, and the instrument placement happening in 2023.


To submit a project for consideration and learn more about the COMET™ Grant Program, please visit:

To learn more about Lunaphore, please visit:



About Lunaphore

Lunaphore Technologies SA is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore has developed a game-changing chip technology that can extract spatial proteomic and genomic data from tumors and transform any simple assay into multiplex spatial biology without complexity. Lunaphore empowers researchers to push the boundaries of research to ultimately develop the next-generation personalized therapies. For further information on Lunaphore and its products, please visit


About COMET™

 COMET™ is a fully automated, sequential immunofluorescence (seqIF™) instrument, able to perform hyperplex staining and imaging, producing high-quality data in a robust and reproducible manner. With superior tissue profiling capabilities, the system allows multiplex analysis of up to 40 different spatial markers per tissue slide without human intervention. COMET™ has a wide range of research applications, allowing for a dramatic improvement in the understanding of disease pathology in areas such as immuno-oncology, neuroscience, and infectious diseases. To learn more about the COMET™ platform, please visit:


For further information contact:


Irene Tamayo

Lunaphore Corporate Communications

Email: [email protected]